

# NOVO-NORDISK AS B

ISIN: DK0062498333 WKN: - Asset Class: **Stock**

## Company



2024/07/17 17:20:00

Price

**919.00**

DKK

Difference

**-5.26%(-51.00)**



## Contact Details

NOVO NORDISK A/S Tel: +45-44-44-88-88  
 -- Fax: +  
 Novo Allé 1 Web: <http://www.novonordisk.com>  
 2880 Bagsværd E-mail: -

## Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023            |                        | 2022            |                        | 2021            |                        |
|---------------------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                       | Assets          | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| <b>Current assets</b>                 | 139,646,000,000 |                        | 108,194,000,000 |                        | 85,595,000,000  |                        |
| <b>Common stock capital</b>           |                 | 451,000,000            |                 | 456,000,000            |                 | 462,000,000            |
| <b>Fixed assets</b>                   | 174,840,000,000 |                        | 133,063,000,000 |                        | 108,913,000,000 |                        |
| <b>Equity capital of a company</b>    |                 | 106,561,000,000        |                 | 83,486,000,000         |                 | 70,746,000,000         |
| <b>Cash and cash equivalents</b>      | 14,392,000,000  |                        | 12,653,000,000  |                        | 10,720,000,000  |                        |
| <b>Accrued liabilities</b>            |                 | 7,391,000,000          |                 | 5,352,000,000          |                 | 5,654,000,000          |
| <b>Other assets</b>                   | -               |                        | -               |                        | -               |                        |
| <b>Current liabilities</b>            |                 | 169,655,000,000        |                 | 120,940,000,000        |                 | 99,516,000,000         |
| <b>Prepayments and accrued income</b> | -               |                        | -               |                        | -               |                        |
| <b>Non-current liabilities</b>        |                 | 38,270,000,000         |                 | 36,831,000,000         |                 | 24,246,000,000         |
| <b>Different income</b>               |                 | -                      |                 | -                      |                 | -                      |
| <b>Other liabilities</b>              |                 | 189,000,000            |                 | 100,000,000            |                 | 360,000,000            |
| <b>Total assets</b>                   | 314,486,000,000 | 314,486,000,000        | 241,257,000,000 | 241,257,000,000        | 194,508,000,000 | 194,508,000,000        |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS    |
| <b>Employees</b>           | 63,370  | 54,393  | 47,792  |
| <b>Equity ratio</b>        | 33.88%  | 34.60%  | 36.37%  |
| <b>Debt-equity ratio</b>   | 195.12% | 188.98% | 174.94% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 20.07% | 19.55% | 19.16% |

# NOVO-NORDISK AS B

ISIN: DK0062498333 WKN: - Asset Class: **Stock**

## Income statement

|                                                                      | 2023            | 2022            | 2021            |
|----------------------------------------------------------------------|-----------------|-----------------|-----------------|
| <b>Turnover</b>                                                      | 232,261,000,000 | 176,954,000,000 | 140,800,000,000 |
| <b>Net income</b>                                                    | 83,683,000,000  | 55,525,000,000  | 47,757,000,000  |
| <b>EBIT</b>                                                          | 13,971,242,000  | 9,322,514,000   | 7,944,056,000   |
| <b>Operating income before taxes</b>                                 | 104,593,000,000 | 69,251,000,000  | 59,104,000,000  |
| <b>Cash Flow</b>                                                     | 108,908,000,000 | 78,887,000,000  | 55,004,000,000  |
| <b>Net interest income</b>                                           | 330,000,000     | -320,000,000    | -180,000,000    |
| <b>Research and development expenses</b>                             | 29,373,000,000  | 21,761,000,000  | 16,292,000,000  |
| <b>Income taxes</b>                                                  | 20,991,000,000  | 13,537,000,000  | 11,323,000,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | 81,000,000      | -189,000,000    | -24,000,000     |
| <b>Revenues per employee</b>                                         | 491,131         | 435,935         | 394,777         |

## Board of Directors

|                       |                               |
|-----------------------|-------------------------------|
| Helge Lund            | Chairman of Supervisory Board |
| Martin MacKay         | Member of Supervisory Board   |
| Sylvie Grégoire       | Member of Supervisory Board   |
| Andreas Fibig         | Member of Supervisory Board   |
| Christina Law         | Member of Supervisory Board   |
| Elisabeth Christensen | Member of Supervisory Board   |
| Henrik Poulsen        | Member of Supervisory Board   |
| Kasim Kutay           | Member of Supervisory Board   |
| Laurence Debroux      | Member of Supervisory Board   |
| Liselotte Hyveled     | Member of Supervisory Board   |
| Mette Bøjer Jensen    | Member of Supervisory Board   |
| Thomas Rantzau        | Member of Supervisory Board   |

## Members of Management Board

|                           |                               |
|---------------------------|-------------------------------|
| Lars Fruergaard Jørgensen | Chairman of Managing Board    |
| Camilla Sylvest           | Member of Executive Committee |
| David Moore               | Member of Executive Committee |
| Doug Langa                | Member of Executive Committee |
| Henrik Wulff              | Member of Executive Committee |
| Karsten Munk Knudsen      | Member of Executive Committee |
| Ludovic Helfgott          | Member of Executive Committee |
| Marcus Schindler          | Member of Executive Committee |
| Martin Holst Lange        | Member of Executive Committee |
| Maziar Mike Doustdar      | Member of Executive Committee |
| Tania Sabroe              | Member of Executive Committee |